Sorafenib treatment inhibits ATP production, leading to activation of AMPK phosphorylation, which interferes with SCD1-mediated monounsaturated fatty acid synthesis via the ATP-AMPK-mTOR- SREBP1 signaling pathway, reducing cell survival and thus killing hepatocellular carcinoma cells [127]. Here, SCD is linked to hepatocellular carcinoma.